Boston Scientific Corporation (NYSE:BSX) Receives $109.43 Consensus PT from Analysts

Shares of Boston Scientific Corporation (NYSE:BSX) have received an average recommendation of “Moderate Buy” from the twenty-four brokerages that are presently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation, twenty have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $108.3636.

BSX has been the topic of several recent analyst reports. UBS Group cut their target price on Boston Scientific from $140.00 to $120.00 and set a “buy” rating on the stock in a research note on Thursday, February 5th. Evercore cut their price objective on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Morgan Stanley reduced their target price on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Canaccord Genuity Group dropped their price target on Boston Scientific from $112.00 to $109.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, Robert W. Baird reduced their price objective on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th.

Insider Activity

In related news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Boston Scientific

A number of institutional investors have recently made changes to their positions in BSX. Steph & Co. purchased a new stake in Boston Scientific during the third quarter valued at $25,000. Financial Consulate Inc. purchased a new stake in Boston Scientific in the 3rd quarter worth $25,000. Murphy & Mullick Capital Management Corp raised its stake in Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares during the period. FWL Investment Management LLC bought a new stake in shares of Boston Scientific during the second quarter valued at approximately $26,000. Finally, Swiss RE Ltd. purchased a new stake in Boston Scientific in the 4th quarter worth $26,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX stock opened at $74.54 on Tuesday. The company has a market capitalization of $110.61 billion, a P/E ratio of 38.42, a PEG ratio of 1.03 and a beta of 0.67. Boston Scientific has a fifty-two week low of $72.69 and a fifty-two week high of $109.50. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.96 and a current ratio of 1.62. The stock has a 50 day moving average price of $89.23 and a two-hundred day moving average price of $96.57.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.78 by $0.02. The company had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Analysts expect that Boston Scientific will post 2.85 earnings per share for the current year.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.